Phase 2
Completed N=12
Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution
Source: ClinicalTrials.gov NCT02874846 ↗Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Apr 2018
Primary outcomePrimary: Change in Intraocular Pressure (IOP) Over Nocturnal Time Period — 22.84; 23.56; 19.38; 23.19 mmHg
Summary
To evaluate effect of Netarsudil Ophthalmic Solution 0.02% on Nocturnal and Diurnal Intraocular Pressure.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Intraocular Pressure (IOP) Over Nocturnal Time Period |
22.84; 23.56; 19.38; 23.19 | — |
| SECONDARY Number of Participants With Adverse Events as a Measure of Safety and Tolerability |
0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- 18 years of age or older.
- Ocular hypertension or open-angle glaucoma in both eyes.
- Unmedicated intraocular pressure > 17 mmHg in one or both eyes and < 30 mmHg in both eyes.
- Corrected visual acuity in each eye equivalent to 20/200 or better.
- Able and willing to give signed informed consent and follow study instructions.
Exclusion Criteria
- Glaucoma with pseudoexfoliation or pigment dispersion component, history of angle closure, narrow angles.
- Intraocular pressure ≥ 30 mmHg.
- Use of ocular medications within 30 days.
- Known hypersensitivity to any component of the test formulations or to medications used routinely during a clinical eye examination.
- Previous eye surgery (other than cataract).
- Ocular trauma within 6 months.
- Clinically significant ocular disease that might interfere with the study.
- Central corneal thickness greater than 620 µm.
Data sourced from ClinicalTrials.gov (NCT02874846). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.